# A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

> **NCT03245229** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Aprocitentan
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT03245229
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-10
- **Primary completion:** 2017-09-18
- **Final completion:** 2017-09-18
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245229, "A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03245229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*